← Back to Search

Vitamin K

Vitamin K2 (menaquinone-7; 360-mcg/d) for Cardiovascular Disease

N/A
Waitlist Available
Led By Norman K Pollock, PhD
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 8 weeks
Awards & highlights

Study Summary

This trial is testing whether vitamin K supplementation can help improve vascular function in people with end-stage renal disease who are undergoing hemodialysis.

Eligible Conditions
  • Cardiovascular Disease
  • Vitamin K Deficiency
  • Renal Disease
  • Hemodialysis
  • Chronic Kidney Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Flow-Mediated Dilation (FMD)
Pulse Wave Velocity (PWV)
Secondary outcome measures
Prothrombin Time

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Vitamin K2 (360-mcg/d)Experimental Treatment1 Intervention
The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
Group II: Placebo-ControlPlacebo Group1 Intervention
The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.

Find a Location

Who is running the clinical trial?

Augusta UniversityLead Sponsor
210 Previous Clinical Trials
84,968 Total Patients Enrolled
Norman K Pollock, PhDPrincipal InvestigatorAugusta University
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
Norman Pollock 2017. "Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03311321.
All > Dialysis > Cardiovascular
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top